Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes

Overview

Homocysteine levels have been found elevated in T1DM patients with Diabetic nephropathy (DN) due to several causes, including dietary deficiencies. Hyperhomocysteinemia induces renal injury and is associated with increasing urinary albumin excretion(UAE). Therefore, the investigators performed a randomized-controlled trial of oral supplementation with vitamin B complex as an adjuvant therapy for nephropathy in pediatric patients with T1DM and assessed its relation to homocysteine levels, glycemic control, microalbuminuria and cystatin C as a marker of nephropathy.

Full Title of Study: “The Role of Vitamin B Complex as an Adjuvant Therapy for Diabetic Nephropathy in Pediatric Patients With Type 1 Diabetes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: March 1, 2018

Detailed Description

This trial included 80 vitamin B12-deficient T1DM patients with nephropathy, despite oral angiotensin-converting enzyme inhibitors . Enrolled patients aged 12-18 years with at least 5 years disease duration and HbA1c ≤8.5%. Patients were randomly assigned into two groups; intervention group who received vitamin B complex once daily orally . The other group did not receive any supplementation and served as a control group. Both groups were followed-up for 12 weeks with assessment of plasma homocysteine, HbA1c, cystatin C and UAE.

Interventions

  • Drug: Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)
    • Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
  • Dietary Supplement: Placebo
    • Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.

Arms, Groups and Cohorts

  • Active Comparator: intervention group
    • Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
  • Placebo Comparator: Control group
    • Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .

Clinical Trial Outcome Measures

Primary Measures

  • Change in plasma homocysteine
    • Time Frame: 12 weeks
    • Change in plasma homocysteine level after 12 weeks of oral vitamin B complex intake

Secondary Measures

  • Change in HbA1c level
    • Time Frame: 12 weeks
    • Change in HbA1c level after 12 weeks of oral vitamin B complex intake

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with type 1 diabetes. – Patients aged 12-18 years with at least 5 years disease duration. – Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion [UAE] 30-299 mg/g creatinine in two of three samples over a 3- to 6- months period despite angiotensin converting enzyme inhibitors) – Hemoglobin A1c (HbA1c) ≤8.5% – Patients on regular visit to clinic. – Patients on regular insulin therapy. Exclusion Criteria:

Patients were excluded if they have any of the following:

  • Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes. – Patients with any evidence of renal impairment due to cause other than diabetes. – Patients with hypertension. – Hepatitis virus infection (B or C) or any evidence of infection. – Taking any vitamins or food supplements one month before study. – Participation in a previous investigational drug study within 3 months preceding screening.

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ain Shams University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nancy Samir Elbarbary, Professor of Pediatrics – Ain Shams University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.